Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013

The Lancet Infectious Diseases

Volumn 16, Issue 12, 2016, Pages 1385-1398

  Degenhardt, Louisa ^a   Charlson, Fiona ^b   Stanaway, Jeff ^c   Larney, Sarah ^a   Alexander, Lily T ^c   Hickman, Matthew ^d   Cowie, Benjamin ^e   Hall, Wayne D ^b,f   Strang, John ^f   Whiteford, Harvey ^b   Vos, Theo ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DAILY LIFE ACTIVITY; DEATH; DISABILITY; DRUG USE; FUNDING; GLOBAL DISEASE BURDEN; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CANCER; LIVER CIRRHOSIS; LOW INCOME COUNTRY; MAJOR CLINICAL STUDY; MIDDLE INCOME COUNTRY; PRIORITY JOURNAL; RISK FACTOR; VIRUS TRANSMISSION; COMPLICATION; COST OF ILLNESS; GLOBAL HEALTH; HIV INFECTIONS; LIFE EXPECTANCY; QUALITY ADJUSTED LIFE YEAR; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE;

COST OF ILLNESS; GLOBAL BURDEN OF DISEASE; GLOBAL HEALTH; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SEX FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84994518946     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30325-5     Document Type: Article

References (63)

1. 1 Naghavi, M, Wang, H, Lozano, R, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
2. 2 Mathers, BM, Degenhardt, L, Phillips, B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372 (2008), 1733–1745.
3. 3 Mathers, BM, Degenhardt, L, Ali, H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 375 (2010), 1014–1028.
4. 4 Nelson, P, Mathers, B, Cowie, B, et al. The epidemiology of viral hepatitis among people who inject drugs: results of global systematic reviews. Lancet 378 (2011), 571–583.
5. 5 Te, HS, Jensen, DM, Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 14 (2010), 1–21.
6. 6 Dore, GJ, Freeman, AJ, Law, M, Kaldor, J, Is severe liver disease a common outcome for people with chronic hepatitis C?. J Gastroenterol Hepatol 17 (2002), 423–430.
7. 7 Degenhardt, L, Whiteford, H, Ferrari, AJ, et al. The global burden of disease attributable to illicit drug use and dependence: results from the GBD 2010 study. Lancet 382 (2013), 1564–1574.
8. 8 GBD 2013 YLDs Collaborators. Global, regional, and national incidence, prevalence and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 743–800.
9. 9 Murray, CJ, Ortblad, KF, Guinovart, C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 1005–1070.
10. 10 Fitzmaurice, C, Dicker, D, Pain, A, et al. The global burden of cancer 2013. JAMA Oncol 1 (2015), 505–527.
11. 11 Stanaway, JD, Flaxman, AD, Naghavi, M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet, 2016 published online July 6. http://dx.doi.org/10.1016/S0140-6736(16)30579-7.
12. 12 Foreman, KJ, Lozano, R, Lopez, AD, Murray, C, Modeling causes of death: an integrated approach using CODEm. Popul Health Metr, 10, 2012, 1.
13. 13 GBD 2013 DALYs and HALE Collaborators, Murray, CJ, Barber, RM, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet 386 (2015), 2145–2191.
14. 14 European Centre for Disease Prevention. HIV/AIDS surveillance in Europe 2014 Solna, Sweden. http://ecdc.europa.eu/en/publications/surveillance_reports/HIV_STI_and_blood_borne_viruses/Pages/HIV_STI_and_blood_borne_viruses.aspx (accessed Sept 10, 2016).
15. 15 Family Health International, Bureau of AIDS TB and STIs Department of Disease Control. The Asian Epidemic Model (AEM) projections for HIV/AIDS in Thailand: 2005–2025, 2008, Family Health International (FHI) and Bureau of AIDS, TB and STIs, Department of Disease Control, Ministry of Public Health, Thailand, Bangkok.
16. 16 Kirby Institute. 2015 Annual surveillance report of HIV, viral hepatitis, STIs, 2015, Kirby Institute, University of New South Wales, Sydney https://kirby.unsw.edu.au/surveillance/2015-annual-surveillance-report-hiv-viral-hepatitis-stis (accessed Sept 10, 2016).
17. 17 Kirby Institute. Australian NSP survey national data report 2015, 2015, Kirby Institute, University of New South Wales, Sydney.
18. 18 UNAIDS. Country reports for Global AIDS Response Progress Reporting, 2014, UNAIDS, Geneva.
19. 19 UNAIDS. UNAIDS Country reports, 2015, Joint United Nations Programme on HIV/AIDS, Geneva http://www.unaids.org/en/regionscountries/countries (accessed Sept 10, 2016).
20. 20 US CDC. HIV/AIDS statistics, 2015, United States Center for Disease Control and Prevention, Atlanta http://www.cdc.gov/hiv/statistics/index.html (accessed Sept 10, 2016).
21. 21 Gouws, E, White, PJ, Stover, J, Brown, T, Short term estimates of adult HIV incidence by mode of transmission: Kenya and Thailand as examples. Sex Transm Infect 82:suppl 3 (2006), iii51–iii55.
22. 22 McMahon, B, The natural history of chronic hepatitis B virus infection. Hepatology 49:5 suppl (2009), S45–S55.
23. 23 Jackson, JB, Wei, L, Liping, F, et al. Prevalence and seroincidence of hepatitis B and hepatitis C infection in high risk people who inject drugs in China and Thailand. Hepat Res Treat, 2014, 2014, 296958.
24. 24 Månsson, A-S, Moestrup, T, Nordenfelt, E, Widell, A, Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis 32 (2000), 253–258.
25. 25 Blomé, MA, Björkman, P, Flamholc, L, Jacobsson, H, Molnegren, V, Widell, A, Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program. J Viral Hepat 18 (2011), 831–839.
26. 26 Hagan, H, McGough, JP, Thiede, H, Weiss, NS, Hopkins, S, Alexander, ER, Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 149 (1999), 203–213.
27. 27 Crofts, N, Aitken, CK, Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria in 1990–1995. Med J Aust 167 (1997), 17–20.
28. 28 Roy, K, Goldberg, D, Taylor, A, et al. A method to detect the incidence of hepatitis C infection among injecting drug users in Glasgow 1993–98. J Infect 43 (2001), 200–205.
29. 29 Abou-Saleh, M, Davis, P, Rice, P, et al. The effectiveness of behavioural interventions in the primary prevention of hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learned. Harm Reduct J, 5, 2008, 25.
30. 30 Turner, KM, Hutchinson, S, Vickerman, P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106 (2011), 1978–1988.
31. 31 Grebely, J, Lima, VD, Marshall, BD, et al. Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996–2012. PLoS One, 9, 2014, e97726.
32. 32 Foley, S, Abou-Saleh, MT, Risk behaviors and transmission of hepatitis C in injecting drug users. Addict Disord Their Treat 8 (2009), 13–21.
33. 33 Craine, N, Hickman, M, Parry, J, et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiol Infect 137 (2009), 1255–1265.
34. 34 Villano, SA, Vlahov, D, Nelson, KE, Lyles, CM, Cohn, S, Thomas, DL, Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 35 (1997), 3274–3277.
35. 35 Maher, L, Jalaludin, B, Chant, KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 101 (2006), 1499–1508.
36. 36 Lucidarme, D, Bruandet, A, Ilef, D, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect 132 (2004), 699–708.
37. 37 Partanen A, Malin K, Perälä R, et al. Risk-Research 2000–2003. Follow-up study using injecting drugs. A-clinic foundation report series No. 52. Helsinki: A-Klinikkasäätiön, 2006 (in Finnish).
38. 38 Van Den Berg, C, Smit, C, Van Brussel, G, Coutinho, R, Prins, M, Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 102 (2007), 1454–1462.
39. 39 Larney, S, Kopinski, H, Beckwith, CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology 58 (2013), 1215–1224.
40. 40 Degenhardt, L, Mathers, B, Vickerman, P, Rhodes, T, Latkin, C, Hickman, M, Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376 (2010), 285–301.
41. 41 Degenhardt, L, Mathers, BM, Wirtz, AL, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010–2012? A review of the six highest burden countries. Int J Drug Policy 25 (2014), 53–60.
42. 42 Swan, T, The hepatitis C treatment pipeline report, 2011, Treatment Action Group, New York City http://www.treatmentactiongroup.org/uploadedFiles/About/Publications/TAG_Publications/2011/HCV%20pipeline%202011%20final.pdf (accessed June 18, 2011).
43. 43 Martin, NK, Vickerman, P, Dore, GJ, Hickman, M, The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS 10 (2015), 374–380.
44. 44 Thokala, P, Simpson, EL, Tappenden, P, et al. Ledipasvir–sofosbuvir for treating chronic hepatitis C: a NICE single technology appraisal—an evidence review group perspective. Pharmacoeconomics 34 (2016), 741–750.
45. 45 Papatheodoridis, GV, Lampertico, P, Manolakopoulos, S, Lok, A, Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53 (2010), 348–356.
46. 46 Liaw, YF, Leung, N, Kao, JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2 (2008), 263–283.
47. 47 Doyle, JS, Aspinall, EJ, Hutchinson, S, et al. Global policy and access to new hepatitis C therapies for people who inject drugs. Int J Public Health 26 (2015), 1064–1071.
48. 48 Coffin, PO, Scott, JD, Golden, MR, Sullivan, SD, Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 54 (2012), 1259–1271.
49. 49 Rein, DB, Smith, BD, Wittenborn, JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med 156 (2012), 263–270.
50. 50 Koretz, RL, Lin, KW, Ioannidis, JP, Lenzer, J, Is widespread screening for hepatitis C justified. BMJ, 350, 2015, g7809.
51. 51 Martin, NK, Vickerman, P, Foster, GR, Hutchinson, SJ, Goldberg, DJ, Hickman, M, Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 54 (2011), 1137–1144.
52. 52 Martin, NK, Vickerman, P, Miners, A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55 (2012), 49–57.
53. 53 Martin, NK, Hickman, M, Hutchinson, SJ, Goldberg, DJ, Vickerman, P, Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 57:suppl 2 (2013), S39–S45.
54. 54 MacArthur, GJ, Minozzi, S, Martin, N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ, 345, 2012, e5945.
55. 55 Gowing, L, Farrell, MF, Bornemann, R, Sullivan, LE, Ali, R, Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev, 8, 2011 CD004145.
56. 56 Hickman, M, De Angelis, D, Vickerman, P, Hutchinson, S, Martin, NK, Hepatitis C virus treatment as prevention in people who inject drugs: Testing the evidence. Curr Opin Infect Dis 28 (2015), 576–582.
57. 57 Mast, EE, Margolis, HS, Fiore, AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR Recomm Rep 54:RR16 (2005), 1–25.
58. 58 Kinner, SA, Degenhardt, L, Coffey, C, Sawyer, S, Hearps, S, Patton, G, Complex health needs in the youth justice system: a survey of community-based and custodial offenders. J Adolesc Health 54 (2014), 521–526.
59. 59 Salomon, JA, Vos, T, Hogan, DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2129–2143.
60. 60 Forouzanfar, MH, Alexander, L, Anderson, HR, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 2287–2323.
61. 61 Vickerman, P, Martin, NK, Roy, A, et al. Is the HCV–HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?. Drug Alcohol Depend 132 (2013), 172–181.
62. 62 WHO. Draft global health sector strategy on viral hepatitis, 2016–2021—the first of its kind, 2016, World Health Organization, Geneva.
63. 63 United Nations. A/70/L.52: Political declaration on HIV and AIDS: on the fast-track to accelerate the fight against HIV and to end the AIDS epidemic by 2030. 2016 High-Level Meeting on ending AIDS; 2016; New York, USA. http://www.unaids.org/sites/default/files/media_asset/2016-political-declaration-HIV-AIDS_en.pdf (accessed Sept 10, 2016).